Innate Pharma (IPHA) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases.
The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma.
Additionally, Innate said it is advancing its Antibody-Drug Conjugate programs, with lead candidate IPH4502 in a phase 1 trial for advanced solid tumors.
Innate is also seeking a partner for lacutamab in T-cell lymphomas and collaborating with AstraZeneca (AZN) on monalizumab, which is in a phase 3 trial for non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.